drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Intravenous anti-EGFR IgG1 monoclonal antibody that blocks ligand-dependent EGFR activation, reduces downstream RAS/MAPK signaling, and can induce antibody-dependent cellular cytotoxicity (ADCC).
nci_thesaurus_concept_id
C1723
nci_thesaurus_preferred_term
Cetuximab
nci_thesaurus_definition
A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.
drug_mesh_term
Cetuximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody targeting EGFR; binds the extracellular domain to block ligand binding and receptor dimerization, inhibiting downstream RAS/MAPK (and PI3K/AKT) signaling. Its Fc can engage ADCC against EGFR-expressing tumor cells.
drug_name
Cetuximab
nct_id_drug_ref
NCT06428500